EU Approves J&J's $30B Actelion Buy, With Conditions
The European Union's antitrust watchdog on Friday gave its seal of approval to Johnson & Johnson's proposed $30 billion acquisition of Swiss rare drug manufacturer Actelion Ltd. under the condition the...To view the full article, register now.
Already a subscriber? Click here to view full article